This open label clinical trial compares the effects of dexamethasone vs usual care on the number of days alive and free of mechanical ventilation at day 28 amon
This meta-analysis pools data from 7 randomized trials to estimate the association between administration of corticosteroids vs usual care or placebo and all-ca
Jan 22, 2021
THURSDAY, Jan. 21, 2021 (HealthDay News) Tocilizumab plus standard care is not superior to standard care alone for improving clinical outcomes among patients with severe or critical COVID-19 and may increase mortality, according to a study published online Jan. 20 in
The BMJ.
Viviane C. Veiga, M.D., Ph.D., from the BP-A Beneficência Portuguesa de São Paulo in Brazil, and colleagues conducted a randomized trial in nine hospitals in Brazil involving adults with confirmed COVID-19 who were receiving supplemental oxygen or mechanical ventilation and had abnormal levels of at least two biomarkers. One hundred twenty-nine patients were enrolled: 65 to tocilizumab plus standard care and 64 to standard care alone.